Ginkgo Bioworks Holdings, Inc. reported a significant decline in financial performance for the third quarter of 2025, with total revenue of $38.8 million, down 56.5% from $89.0 million in the same period last year. The company's Cell Engineering segment generated $29.4 million, a decrease of $45.7 million compared to $75.1 million in Q3 2024, primarily due to the absence of non-cash revenue from a previously terminated contract. Biosecurity revenue also fell to $9.5 million from $14.0 million, reflecting reduced activity with government clients. For the nine months ended September 30, 2025, total revenue was $136.8 million, down from $183.2 million in the prior year.
The company's operating expenses decreased to $128.9 million from $144.3 million year-over-year, driven by reductions in research and development and general administrative costs. However, Ginkgo Bioworks still reported a net loss of $80.8 million for the quarter, compared to a loss of $56.4 million in Q3 2024. The nine-month net loss was $232.0 million, a notable improvement from a loss of $439.5 million in the same period last year, largely due to lower operating expenses and restructuring efforts.
Strategically, Ginkgo has been focusing on restructuring its operations, which included a workforce reduction of over 50% and the consolidation of facilities. The company has also made significant investments in marketable securities, totaling $350.8 million as of September 30, 2025. Ginkgo's cash and cash equivalents decreased to $111.1 million from $561.6 million at the end of 2024, reflecting ongoing operational expenditures and investments.
In terms of operational metrics, Ginkgo's employee headcount has been significantly reduced as part of its restructuring plan, which is expected to be completed in 2025. The company has also launched new services in its Cell Engineering segment, including data generation products aimed at supporting AI-driven drug development. Despite the challenges, Ginkgo remains optimistic about its future, projecting that its current cash reserves will be sufficient to fund operations for at least the next 12 months.
Looking ahead, Ginkgo Bioworks aims to stabilize its operations and continue investing in its Foundry and Codebase, while also exploring potential acquisitions to enhance its capabilities. The company is committed to improving its financial performance and adapting its business model to better align with market demands.
About Ginkgo Bioworks Holdings, Inc.
Ginkgo BioWorks is a biotechnology company specializing in cell engineering and biosecurity. It provides R&D services, tools, and platforms to develop biologics, gene therapies, vaccines, and agricultural solutions. Its core value lies in making biology easier to engineer through automation, AI, and data assets, serving industries like pharmaceuticals, agriculture, industrial biotech, and government, with a focus on innovation, scalability, and biosecurity.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.